May 02, 2025

Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia

Two experts discuss strategies and clinical considerations when treating patients with AML who are ineligible for intensive chemotherapy as well as those who are eligible for intensive chemotherapy.

The ASCO Post

May 01, 2025

Health Care Faces New Immigration Reality

Health care facilities face new challenges as sensitive locations policy protecting them from immigration enforcement was rescinded in January 2025, requiring new protocols for patient protection.

Conexiant

May 01, 2025

Explore the latest in retinal disorder research and treatment at the global Retina World Congress, where leading experts share best practices and advancements.

Retinal Physician

May 01, 2025

Ocular Surface Disease Treatments in the Pipeline

Potential treatments address inflammation and tear production, offer alternative mechanisms of action, or address a subset of dry eye.

Ophthalmology Management

May 01, 2025

Discover the latest advancements in the diagnosis and treatment of retinal diseases at the premier Retina World Congress.

Retinal Physician

April 30, 2025

New Phase III Data on Brensocatib Therapy

Phase III trial results show that once-daily brensocatib reduces pulmonary exacerbations and slows lung function decline in patients with bronchiectasis.

Conexiant

April 30, 2025

New Phase III Data: Sotatercept for PAH

Sotatercept reduced the composite risk of death, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension by nearly 75% compared with placebo in high-risk patients in a phase III trial.

Conexiant

April 29, 2025

Can Five Proteins Predict Liver Disease?

"Imagine if we could predict risk of metabolic dysfunction-associated steatotic liver disease (MASLD) years before it starts."

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant